FOXP3 Inhibits Angiogenesis by Downregulating VEGF in Breast Cancer

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2018 Jul 5

PMID 29970908

Citations 37

Authors

Xiaoju Li

Yuan Gao

Jialin Li

Kuo Zhang

Jun Han

Weina Li

Qiang Hao

Wangqian Zhang

Shuning Wang

Cheng Zeng

Wei Zhang

Yingqi Zhang

Meng Li

Cun Zhang

Affiliations

Soon will be listed here.

Abstract

Forkhead box P3 (FOXP3), an X-linked tumor suppressor gene, plays an important role in breast cancer. However, the biological functions of FOXP3 in breast cancer angiogenesis remain unclear. Here we found that the clinical expression of nuclear FOXP3 was inversely correlated with breast cancer angiogenesis. Moreover, the animal study demonstrated that FOXP3 significantly reduced the microvascular density of MDA-MB-231 tumors transplanted in mice. The cytological experiments showed that the supernatant from FOXP3-overexpressing cells exhibited a diminished ability to stimulate tube formation and sprouting in HUVECs in vitro. In addition, expression of vascular endothelial growth factor (VEGF) was downregulated by FOXP3 in breast cancer cell lines. Luciferase reporter assays and chromatin immunoprecipitation assays demonstrated that FOXP3 can directly interact with the VEGF promoter via specific forkhead-binding motifs to suppress its transcription. Importantly, the inhibitory effects of FOXP3 in the supernatant on tube formation and sprouting in HUVECs could be reversed by adding VEGF in vitro. Nuclear FOXP3 expression was inversely correlated with VEGF expression in clinical breast cancer tissues, and FOXP3 downregulation and VEGF upregulation were both correlated with reduced survival in breast cancer data sets in the Kaplan-Meier plotter. Taken together, our data demonstrate that FOXP3 suppresses breast cancer angiogenesis by downregulating VEGF expression.

Citing Articles

The molecular mechanism of ginsenoside Rh2 and its octyl ester derivative on anti-angiogenesis in cancer treatment: The battle between PI3K and ROS.

Hu Q, Zhong X, Feng H, Li X, Zhang Z, Pan Y J Ginseng Res. 2025; 49(2):208-222.

PMID: 40061477 PMC: 11889380. DOI: 10.1016/j.jgr.2025.01.002.

Advances in Foxp3+ regulatory T cells (Foxp3+ Treg) and key factors in digestive malignancies.

Wang W, Ding M, Wang Q, Song Y, Huo K, Chen X Front Immunol. 2024; 15:1404974.

PMID: 38919615 PMC: 11196412. DOI: 10.3389/fimmu.2024.1404974.

Vascular Endothelial Growth Factor Expression by Immunohistochemistry as a Possible Indicator of Prognosis in Invasive Breast Carcinoma of No Special Type.

Sindhura N, Kaumudi K Int J Appl Basic Med Res. 2024; 14(2):124-130.

PMID: 38912361 PMC: 11189271. DOI: 10.4103/ijabmr.ijabmr_17_24.

A model based on immunogenic cell death-related genes predicts prognosis and response to immunotherapy in kidney renal clear cell carcinoma.

Dong P, Zhao L, Zhao L, Zhang J, Lu G, Zhang H Transl Cancer Res. 2024; 13(1):249-267.

PMID: 38410237 PMC: 10894358. DOI: 10.21037/tcr-23-214.

Identification of FOXP3 epithelial cells contributing to pancreatic proliferation and angiogenesis.

Gong R, Chen X, Sun X, Zhang Y, Wang J, Yu Q Am J Physiol Cell Physiol. 2023; 326(1):C294-C303.

PMID: 38047300 PMC: 11192472. DOI: 10.1152/ajpcell.00461.2023.

References

Zheng Y, Josefowicz S, Kas A, Chu T, Gavin M, Rudensky A . Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007; 445(7130):936-40. DOI: 10.1038/nature05563. View

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

Rudra D, deRoos P, Chaudhry A, Niec R, Arvey A, Samstein R . Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat Immunol. 2012; 13(10):1010-9. PMC: 3448012. DOI: 10.1038/ni.2402. View

Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L . FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest. 2007; 117(12):3765-73. PMC: 2075479. DOI: 10.1172/JCI32538. View

Gyorffy B, Schafer R . Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res Treat. 2008; 118(3):433-41. DOI: 10.1007/s10549-008-0242-8. View

Zhang C, Xu Y, Hao Q, Wang S, Li H, Li J . FOXP3 suppresses breast cancer metastasis through downregulation of CD44. Int J Cancer. 2015; 137(6):1279-90. DOI: 10.1002/ijc.29482. View

Douglass S, Meeson A, Overbeck-Zubrzycka D, Brain J, Bennett M, Lamb C . Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12. J Pathol. 2014; 234(1):74-85. DOI: 10.1002/path.4381. View

Szylberg L, Karbownik D, Marszalek A . The Role of FOXP3 in Human Cancers. Anticancer Res. 2016; 36(8):3789-94. View

Rudensky A . Regulatory T cells and Foxp3. Immunol Rev. 2011; 241(1):260-8. PMC: 3077798. DOI: 10.1111/j.1600-065X.2011.01018.x. View

10.

Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W . FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007; 129(7):1275-86. PMC: 1974845. DOI: 10.1016/j.cell.2007.04.034. View

11.

Roskoski Jr R . Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 2007; 62(3):179-213. DOI: 10.1016/j.critrevonc.2007.01.006. View

12.

Manalo D, Rowan A, Lavoie T, Natarajan L, Kelly B, Ye S . Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2004; 105(2):659-69. DOI: 10.1182/blood-2004-07-2958. View

13.

Feng Q, Zhang C, Lum D, Druso J, Blank B, Wilson K . A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nat Commun. 2017; 8:14450. PMC: 5316898. DOI: 10.1038/ncomms14450. View

14.

Lambrechts D, Lenz H, de Haas S, Carmeliet P, Scherer S . Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013; 31(9):1219-30. DOI: 10.1200/JCO.2012.46.2762. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Wang L, Liu R, Li W, Chen C, Katoh H, Chen G . Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009; 16(4):336-46. PMC: 2758294. DOI: 10.1016/j.ccr.2009.08.016. View

17.

Bose D, Meric-Bernstam F, Hofstetter W, Reardon D, Flaherty K, Ellis L . Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010; 11(4):373-82. DOI: 10.1016/S1470-2045(09)70341-9. View

18.

Brunkow M, Jeffery E, Hjerrild K, Paeper B, Clark L, Yasayko S . Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001; 27(1):68-73. DOI: 10.1038/83784. View

19.

Liu R, Wang L, Chen G, Katoh H, Chen C, Liu Y . FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. Cancer Res. 2009; 69(6):2252-9. PMC: 2715174. DOI: 10.1158/0008-5472.CAN-08-3717. View

20.

Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View